|
|
Learning Objective:
By the end of the presentation participants will be able to:
1.Understand the key components of risk reduction strategies and the medical model (neurobiology) of substance use as they apply to hepatitis prevention
2.Understand the role of hepatitis A and B vaccination as part of a comprehensive hepatitis prevention program
Background:
Injection drug users (IDUs) are at high risk for bloodborne infections such as Human Immunodeficiency Virus (HIV), Hepatitis C (HCV) and Hepatitis B virus (HBV). Despite this risk, IDUs often do not receive preventive vaccination for hepatitis A and B. IDUs are willing to obtain vaccination when offered; however, often when IDUs interact with healthcare providers, vaccination is forgotten in the perceived greater importance of treating the current problem.
Setting:
Healthcare settings that interact with substance users.
Population e.g. API Youth, MSM, IDU:
Substance users (both injection drug users and non-injection drug users) are at risk for acquiring HIV, HAV, HBV, and HCV either directly due to substance use (e.g., IDU) or indirectly through risky sexual practices as the result of drug use or in order to obtain drugs of use.
Project Description:
Drs. Altice and Bruce work with HIV/HCV co-infected drug users. Mr. Farrell runs a large SEP in New York working with this population. All are well versed and experienced in this field.
Results/Lessons Learned:
This presentation will serve as a review of risk reduction strategies as they apply to preventative health vaccination for HAV/HBV and screening of HCV.
See more of H2 - Hepatitis Education Challenges in Substance Abuse Settings
See more of The 2005 National Viral Hepatitis Prevention Conference